IL241326B - Allogenic cell containing compositions and uses thereof in immunotherapy - Google Patents
Allogenic cell containing compositions and uses thereof in immunotherapyInfo
- Publication number
- IL241326B IL241326B IL241326A IL24132615A IL241326B IL 241326 B IL241326 B IL 241326B IL 241326 A IL241326 A IL 241326A IL 24132615 A IL24132615 A IL 24132615A IL 241326 B IL241326 B IL 241326B
- Authority
- IL
- Israel
- Prior art keywords
- immunotherapy
- cell containing
- containing compositions
- allogenic cell
- allogenic
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/796,171 US9320794B2 (en) | 2006-11-13 | 2013-03-12 | Ablative immunotherapy |
PCT/US2014/022287 WO2014164396A1 (en) | 2013-03-12 | 2014-03-10 | Ablative immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
IL241326A0 IL241326A0 (en) | 2015-11-30 |
IL241326B true IL241326B (en) | 2021-05-31 |
Family
ID=51658863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL241326A IL241326B (en) | 2013-03-12 | 2015-09-08 | Allogenic cell containing compositions and uses thereof in immunotherapy |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2970910A4 (en) |
JP (1) | JP6538647B2 (en) |
KR (1) | KR102265276B1 (en) |
CN (2) | CN106581673A (en) |
AU (2) | AU2014249374A1 (en) |
BR (1) | BR112015022974A8 (en) |
CA (1) | CA2904853A1 (en) |
IL (1) | IL241326B (en) |
PH (1) | PH12015502086A1 (en) |
SG (2) | SG11201507350WA (en) |
WO (1) | WO2014164396A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151309B (en) * | 2018-02-14 | 2022-02-15 | 上海美杰医疗科技有限公司 | Preoperative planning method and equipment for multi-modal ablation therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
CN1806849A (en) * | 2005-01-19 | 2006-07-26 | 上海三维生物技术有限公司 | Method of treating tumors |
US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
WO2009095033A1 (en) * | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
-
2014
- 2014-03-10 EP EP14779681.7A patent/EP2970910A4/en not_active Ceased
- 2014-03-10 JP JP2016500938A patent/JP6538647B2/en active Active
- 2014-03-10 SG SG11201507350WA patent/SG11201507350WA/en unknown
- 2014-03-10 WO PCT/US2014/022287 patent/WO2014164396A1/en active Application Filing
- 2014-03-10 KR KR1020157028277A patent/KR102265276B1/en active IP Right Grant
- 2014-03-10 CN CN201710016168.5A patent/CN106581673A/en active Pending
- 2014-03-10 CA CA2904853A patent/CA2904853A1/en not_active Abandoned
- 2014-03-10 CN CN201480014494.7A patent/CN105102613A/en active Pending
- 2014-03-10 AU AU2014249374A patent/AU2014249374A1/en not_active Abandoned
- 2014-03-10 BR BR112015022974A patent/BR112015022974A8/en not_active Application Discontinuation
- 2014-03-10 SG SG10201707446PA patent/SG10201707446PA/en unknown
-
2015
- 2015-09-08 IL IL241326A patent/IL241326B/en active IP Right Grant
- 2015-09-11 PH PH12015502086A patent/PH12015502086A1/en unknown
-
2020
- 2020-02-21 AU AU2020201309A patent/AU2020201309A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20150138234A (en) | 2015-12-09 |
CA2904853A1 (en) | 2014-10-09 |
AU2020201309A1 (en) | 2020-03-12 |
CN106581673A (en) | 2017-04-26 |
BR112015022974A2 (en) | 2017-07-18 |
JP6538647B2 (en) | 2019-07-03 |
JP2016518319A (en) | 2016-06-23 |
PH12015502086A1 (en) | 2016-01-18 |
EP2970910A1 (en) | 2016-01-20 |
KR102265276B1 (en) | 2021-06-16 |
CN105102613A (en) | 2015-11-25 |
SG10201707446PA (en) | 2017-10-30 |
IL241326A0 (en) | 2015-11-30 |
SG11201507350WA (en) | 2015-10-29 |
EP2970910A4 (en) | 2016-11-16 |
AU2014249374A1 (en) | 2015-09-24 |
BR112015022974A8 (en) | 2019-11-26 |
WO2014164396A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211620A1 (en) | Natural killer cells and uses thereof | |
IL242273B (en) | Methods and compositions for enhancing cd4+ regulatory t cells | |
SG11201408697QA (en) | Methods and compositions for natural killer cells | |
GB201622354D0 (en) | SC-� Cells and Compositions and methods for generating the same | |
GB201321693D0 (en) | Composition and uses thereof | |
EP2968107A4 (en) | Cosmetic compositions and uses thereof | |
EP2854530A4 (en) | Compositions and methods for -glucan immunotherapy | |
HK1206970A1 (en) | Antigenic compositions and methods | |
IL276126B (en) | Compositions comprising l-4-chlorokynurenine and uses thereof | |
EP3072953A4 (en) | Cell culture container and container in which cell culture has been accommodated | |
EP3007720A4 (en) | Compositions comprising gc- macrophage activating factor and uses thereof | |
GB201322456D0 (en) | Radiotracer compositions and methods | |
HK1222561A1 (en) | Compositions and methods for use in oncology | |
EP2964610A4 (en) | Vinylsulfone-based 18f-labeling compositions and methods and uses thereof | |
HK1210436A1 (en) | Novel cell compositions and methods | |
IL241326B (en) | Allogenic cell containing compositions and uses thereof in immunotherapy | |
IL243091B (en) | Compositions and methods for use in oncology | |
RS56379B1 (en) | Dermo-protective and dermo-balancing composition | |
GB201210989D0 (en) | Composition and device | |
HK1219292A1 (en) | Cd14 cell compositions and methods of using same cd14 | |
GB201320632D0 (en) | Electrochemical cells and components thereof | |
GB201301022D0 (en) | Composition and uses thereof | |
GB201308242D0 (en) | Compositions and uses thereof | |
GB201221083D0 (en) | Electrochemical cells and components thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |